According to the scheme, which was launched by the Ministry of Health and Family Welfare in August 2009, the informers would be suitably rewarded for providing information in respect of movement of spurious drugs to regulatory authorities.
A reward of up to a maximum of 20 per cent (not exceeding to Rs 25 lakh) of the total cost of consignments of fake drugs seized will be payable to any informer.
"After investigations, all the complaints received so far have been found to be fictitious. No person has accordingly been rewarded under the scheme till date," it said in reply to an RTI application filed by PTI.
As many as 572 drugs samples were declared spurious or adulterated between 2008 and July 2013.
Of these, 157 samples were reported adulterated in 2008-09, 117 during 2009-10, 95 in 2010-11, 133 during 2011-12 and 70 between April 2012 and July 2013, the reply said.
"Internationally, the vested interests are supplying spurious medicines manufactured by them but with 'Made in India' label," said a background note on the reward scheme.
There is no dearth of good intentioned people who may wish to work for the country's interests as the whistle blowers in eradicating the menace, it said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
